Alteplase is a glycoprotein similar to fibrinogen activator that activates fibrinolytic enzymes to dissolve fibrin clots and thus thrombi, and is mainly used in the acute phase of myocardial infarction. Fibrin is the main component in the process of blood clotting, which can network blood cells and form substances such as blood scabs and blood clots, which are normally generated only when the body is injured and used to block wounds, but patients with high blood lipids and coagulation abnormalities may generate a large number of fibrinolytic enzymes in blood vessels and form blood clots to block blood vessels. And fibrinolytic enzyme can dissolve fibrin and inhibit thrombus generation. Atipase is a synthetic fibrinolytic enzyme analog through genetic recombination technology, which can stimulate the body to produce fibrinolytic enzyme, dissolve fibrin in blood vessels, and release the networked blood cells, thus contributing to the dissolution of blood clots. Myocardial infarction is mostly due to coronary artery thrombosis, resulting in acute ischemia and massive necrosis of the myocardium, so alteplase is usually used to treat myocardial infarction. Alteplase needs to be used under medical supervision, and may cause clotting disorders, leading to bleeding, most often at the injection site, and rarely blood in the stool and intracranial hemorrhage.